Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Chen, Daohong ^a   Liu, Xiaolei ^a,b   Zhang, Weiping ^c   Shi, Yuguang ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 26; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ENERGY EXPENDITURE; ENZYME INACTIVATION; ENZYME REGULATION; FEMALE; GENE; GENE DELETION; GENE TARGETING; GLUCOSE INTOLERANCE; GPR26 GENE; HETEROZYGOSITY; HOMEOSTASIS; HOMOZYGOSITY; HYPERINSULINEMIA; HYPERPHAGIA; HYPOTHALAMUS; HYPOTHALAMUS FUNCTION; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN FUNCTION; SATIETY; SIGNAL TRANSDUCTION;

ADIPOSITY; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DIET; DYSLIPIDEMIAS; ENERGY METABOLISM; ENZYME ACTIVATION; GENE SILENCING; GENE TARGETING; GLUCOSE INTOLERANCE; HYPERINSULINISM; HYPERPHAGIA; HYPOTHALAMUS; MICE; MICE, INBRED C57BL; OBESITY; PHOSPHORYLATION; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, G-PROTEIN-COUPLED; WEIGHT LOSS;

CAENORHABDITIS ELEGANS; MAMMALIA; MUS;

EID: 84864007945     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040764     Document Type: Article

References (39)

1. Rejeski WJ, Ip EH, Bertoni AG, Bray GA, Evans G, et al. (2012) Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med 366: 1209-1217.
2. Stein CJ, Colditz GA, (2004) The epidemic of obesity. J Clin Endocrinol Metab 89: 2522-2525.
3. Kahn BB, Flier JS, (2000) Obesity and insulin resistance. J Clin Invest 106: 473-481.
4. Farrigan C, Pang K, (2002) Obesity market overview. Nat Rev Drug Discov 1: 257-258.
5. Jandacek RJ, Woods SC, (2004) Pharmaceutical approaches to the treatment of obesity. Drug Discov Today 9: 874-880.
6. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, et al. (2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3: 167-175.
7. Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, et al. (2003) The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A 100: 4903-4908.
8. Xu YL, Jackson VR, Civelli O, (2004) Orphan G protein-coupled receptors and obesity. Eur J Pharmacol 500: 243-253.
9. Lee DK, Lynch KR, Nguyen T, Im DS, Cheng R, et al. (2000) Cloning and characterization of additional members of the G protein-coupled receptor family. Biochim Biophys Acta 1490: 311-323.
10. Bresnick JN, Skynner HA, Chapman KL, Jack AD, Zamiara E, et al. (2003) Identification of signal transduction pathways used by orphan g protein-coupled receptors. Assay Drug Dev Technol 1: 239-249.
11. Ashrafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, et al. (2003) Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 421: 268-272.
12. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, et al. (2001) Circulating ghrelin levels are decreased in human obesity. Diabetes 50: 707-709.
13. Myers MG, Leibel RL, Seeley RJ, Schwartz MW, (2010) Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab 21: 643-651.
14. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, et al. (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784-1792.
15. Hardie DG, (2007) AMPK and SNF1: Snuffing Out Stress. Cell Metab 6: 339-340.
16. Zhang BB, Zhou G, Li C, (2009) AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9: 407-416.
17. Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, et al. (2004) AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 279: 12005-12008.
18. Kola B, (2008) Role of AMP-activated protein kinase in the control of appetite. J Neuroendocrinol 20: 942-951.
19. Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, et al. (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO Journal 23: 833-843.
20. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174.
21. Dong C, Wang S, Li WD, Li D, Zhao H, et al. (2003) Interacting genetic loci on chromosomes 20 and 10 influence extreme human obesity. Am J Hum Genet 72: 115-124.
22. Chen Y, Hu C, Hsu CK, Zhang Q, Bi C, et al. (2002) Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology 143: 2469-2477.
23. Li J, Romestaing C, Han X, Li Y, Hao X, et al. (2010) Cardiolipin remodeling by ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity. Cell Metab 12: 154-165.
24. Koza RA, Nikonova L, Hogan J, Rim JS, Mendoza T, et al. (2006) Changes in gene expression foreshadow diet-induced obesity in genetically identical mice. PLoS Genet 2: e81.
25. Kahn BB, Alquier T, Carling D, Hardie DG, (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25.
26. Xue B, Kahn BB, (2006) AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J Physiol 574: 73-83.
27. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, et al. (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428: 569-574.
28. Yang CS, Lam CK, Chari M, Cheung GW, Kokorovic A, et al. (2010) Hypothalamic AMP-activated protein kinase regulates glucose production. Diabetes 59: 2435-2443.
29. Lee JM, Seo WY, Song KH, Chanda D, Kim YD, et al. (2010) AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner. J Biol Chem 285: 32182-32191.
30. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646.
31. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, et al. (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13: 376-388.
32. Hurley RL, Barre LK, Wood SD, Anderson KA, Kemp BE, et al. (2006) Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem 281: 36662-36672.
33. Sandoval DA, Obici S, Seeley RJ, (2009) Targeting the CNS to treat type 2 diabetes. Nat Rev Drug Discov 8: 386-398.
34. Despres JP, Golay A, Sjostrom L, (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121-2134.
35. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, et al. (2005) Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280: 25196-25201.
36. Di Marzo V, Despres JP, (2009) CB1 antagonists for obesity-what lessons have we learned from rimonabant? Nat Rev Endocrinol 5: 633-638.
37. King A, (2010) Prevention: Neuropsychiatric adverse effects signal the end of the line for rimonabant. Nat Rev Cardiol 7: 602.
38. Zhang LL, Wang JJ, Liu Y, Lu XB, Kuang Y, et al. (2011) GPR26-deficient mice display increased anxiety- and depression-like behaviors accompanied by reduced phosphorylated cyclic AMP responsive element-binding protein level in central amygdala. Neuroscience 196: 203-214.
39. Atlantis E, Goldney RD, Wittert GA, (2009) Obesity and depression or anxiety. BMJ 339: b3868.